Navigation Links
NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
Date:6/10/2008

IV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over other pain therapies. NeurogesX' marketing authorization application (MAA) to the European Medicines Agency (EMEA) was accepted for review in September 2007 and NeurogesX plans to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) in 2008 for PHN.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected benefits of NeurogesX' lead product candidate, NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks rel
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
5. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
6. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
7. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
8. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
9. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
10. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
11. Anpath Group, Inc. Announces Addition of MRSA and VRE Claims for Its EnviroTru(R) Disinfectant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  Wrightington, Wigan and Leigh ... MDRX ) are delighted to announce WWL,s decision to ... information system. The system will be implemented across all ... WWL delivers healthcare in the future. ... on-time and on-budget system implementations as well as its ...
(Date:9/30/2014)... STUDY OBJECTIVES The objective of ... an overview of the current and future characteristics ... key objective is to present a comprehensive analysis ... important tool in the treatment of various diseases. ... within the protein therapeutics market, which includes peptide ...
(Date:9/30/2014)... 2014  According to their CEO, Rob ... trials is going through a complete transformation with ... of the current clinical trial management process isn,t ... clinical trials, which will ultimately drive the prescription ... company has been recognized by the National Cancer ...
Breaking Medicine Technology:Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2
(Date:10/1/2014)... October is national Breast Cancer Awareness ... plans while raising money for breast cancer research. Pelican ... Month in the effort to find a cure. ... importance of having access to clean, healthy water. Research ... to certain forms of cancer. , The Problem ...
(Date:10/1/2014)... October 01, 2014 Dr. Saj Jivraj, ... and prosthodontists, is traveling to Chennai, India, tomorrow to ... Oct. 2 and 3. , Dr. Jivraj is founder ... and Oxnard, Calif., and one of the world’s foremost ... and replacement. He is speaking to the Indian Society ...
(Date:10/1/2014)... Two bicyclists began a journey on September ... in an effort to raise funds and awareness to ... a father-daughter team, plan to bike more than 4,000 ... finishing in Key West Florida. Funds raised along ... national nonprofit organization that assists post-9/11 service members, their ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 After undergoing ... right chamber of commerce to join, Living Well Assisted ... of Commerce in Marin County, the home of its ... at the moment, and the thought of adding one ... decided to keep looking for the right chamber to ...
(Date:10/1/2014)... This October, Request A Test , a leading ... 10% off all testing for Diabetes . Customers ... save. The Center for Disease Control (CDC) reports that ... Diabetes. Because many people do not display symptoms, it ... serious health problems. Blood testing can help a person ...
Breaking Medicine News(10 mins):Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 3Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 4Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 5Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2Health News:Living Well Joins San Rafael Chamber of Commerce 2Health News:Living Well Joins San Rafael Chamber of Commerce 3Health News:Request A Test Offers 10% off Diabetes Testing in October 2014 2Health News:Request A Test Offers 10% off Diabetes Testing in October 2014 3
... Network, re-opens in centrally located Family First Health Center; Members now ... access by ... Healthy,Community Pharmacy celebrated its grand re-opening at 116 South George,Street in ... for thousands of local York residents who are part of the,Healthy ...
... with Eculizumab in Patients with Other,Rare Complement-Mediated ... Conn., Nov. 10 Alexion,Pharmaceuticals, Inc. (Nasdaq: ... American,Society of Hematology (ASH) has published additional ... for patients with paroxysmal,nocturnal hemoglobinuria (PNH). Data ...
... Angeles, Calif. Nov. 10, 2008Researchers at the University of ... the regulation and differentiation of neural stem cells. ... a key role in the differentiation of neural stem ... differentiation as stem cells begin to grow into neurons. ...
... For mini-strokes, or transient ischemic attacks (TIAs), both overdiagnosis ... real underlying illness. Underdiagnosis leaves a patient at ... to erroneous therapies with potential side effects. , And ... the neurological dysfunction that results is so brief. ...
... YORK, Nov. 10 Touchstone Health HMO, Inc. ... Prescription Drug (MA-,PD) plans in New York will ... cost savings available to them in 2009. When ... Medicare beneficiaries will be,able to take advantage of ...
... Monoxide Awareness Week Begins Today, SACRAMENTO, ... Monoxide (CO) Awareness Week begins today and ... to take steps to help protect themselves ... weather turns cool., (Photo: http://www.newscom.com/cgi-bin/prnh/20081110/CLM100-a ...
Cached Medicine News:Health News:Capital BlueCross Sponsors Healthy Community Pharmacy's Move to New Community-Focused Location in York 2Health News:Capital BlueCross Sponsors Healthy Community Pharmacy's Move to New Community-Focused Location in York 3Health News:Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting 2Health News:Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting 3Health News:Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting 4Health News:USC researchers identify key mechanism that regulates the development of stem cells into neurons 2Health News:3 clinical features identified to avoid misdiagnosis of TIAs 2Health News:Touchstone Health Responds to Economic Slowdown With Cost Savings and Added Benefits on 2009 Plans 2Health News:Protect Your Family From 'The Silent Killer' This Winter 2Health News:Protect Your Family From 'The Silent Killer' This Winter 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: